Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
Youssef El-Ahmad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
Kaitlyn J. Andreano et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER plus Breast Cancer
Jun Liang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927
Sharada S. Labadie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan et al.
CELL (2019)
The 25th Anniversary of the Buchwald-Hartwig Amination: Development, Applications, and Outlook
Paola A. Forero-Cortes et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2019)
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ER covalent antagonist (SERCA)
Nathalie Rioux et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Mehmet Kahraman et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
George S. Tria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Synthesis of Selective Estrogen Receptor Degrader GDC-0810 via Stereocontrolled Assembly of a Tetrasubstituted All-Carbon Olefin
Scott Savage et al.
JOURNAL OF ORGANIC CHEMISTRY (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health
Balkees Abderrahman et al.
ENDOCRINOLOGY (2018)
Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
Simon J. Johnston et al.
ONCOLOGY AND THERAPY (2018)
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani et al.
CLINICAL CANCER RESEARCH (2017)
Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer
Peter G. Smith et al.
CANCER RESEARCH (2017)
Breast Cancer Statistics, 2015: Convergence of Incidence Rates Between Black and White Women
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Sean W Fanning et al.
eLife (2016)
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER plus breast cancer
James D. Joseph et al.
ELIFE (2016)
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
Fiona Garner et al.
ANTI-CANCER DRUGS (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten et al.
CANCER DISCOVERY (2015)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
Keren Merenbakh-Lamin et al.
CANCER RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Tamoxifen Resistance in Breast Cancer
Minsun Chang
BIOMOLECULES & THERAPEUTICS (2012)
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)
S. Ohno et al.
ANNALS OF ONCOLOGY (2010)
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Kendall W. Nettles et al.
NATURE CHEMICAL BIOLOGY (2008)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Drugs as CYP3A probes, inducers, and inhibitors
Yi-Tong Liu et al.
DRUG METABOLISM REVIEWS (2007)
The Pictet-Spengler reaction: Efficient carbon-carbon bond forming reaction in heterocyclic synthesis
So Won Youn
ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL (2006)
Share Paper
